Skip to main content
All lobbying filings

Harmony Biosciences

Harmony Biosciences filed a Q2 report for Harmony Biosciences on July 21, 2025.

Lobbying for Harmony Biosciences · pharmaceuticals

As filed: HARMONY BIOSCIENCES for HARMONY BIOSCIENCES.

All filings by Harmony Biosciences · Everything Harmony Biosciences has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Expenses
$150,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

HR 946/ S 1862 ORPHAN Cures Act S 832 Ensuring Pathways to Innovative Cures (EPIC) Act HR 1262/ S 932 Give Kids a Chance Act HR 1672 Maintaining Investments in New Innovation Act S 705 Innovation in Pediatric Drugs Act

 Bills named in this filing 3
  • H.R. 946
    ORPHAN Cures Act
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • H.R. 1672
    Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem